RET and ovarian cancer: Our results showed that RET R693H and A750T mutants could promote the viability, colony formation and activation of the RET-MAPK and RET-AKT signaling pathway in ovarian cancer, and the RET inhibitor vandetanib could significantly decrease cell viability and signal transduction at 500 nM.